Autologous hematopoietic stem cell transplantation (auto-HSCT) is a crucial therapeutic modality for high-risk or relapsed lymphoma in adults with HIV infection. However, compared with Europe and American countries, China still faces significant gaps in the standardized and specialized management of auto-HSCT for HIV-positive patients. To address this issue, the National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Yangtze River Delta Collaborative Group for Diagnosis and Treatment of Vulnerable Population with HIV/AIDS, AIDS Group, Society of Tropical Diseases and. Parasitology, Zhejiang Medical Association, jointly with experts from relevant fields, have developed this expert consensus by integrating the experience of major domestic auto-HSCT centers and the latest international research advances. This consensus covers multiple aspects, including pre-transplant evaluation and preparation (indications for auto-HSCT and patient assessment), implementation of auto-HSCT (timing of hematopoietic stem cell mobilization and collection, transplant procedure, management principles for related complications, and peri-transplant care), and post-transplant follow-up management (post-transplant maintenance therapy, hematopoietic reconstitution, immune reconstitution, and follow-up). It aims to provide scientific and standardized guidance for domestic clinicians, optimize the therapeutic outcomes of auto-HSCT in patients with HIV-associated lymphoma, and improve their long-term survival benefits.